Country | Type | Number | Dated | Case |
China | Issued Patent | ZL201780074122.7 | 10/29/2024 | 2017-017 |
Australia | Issued Patent | 2017335883 | 09/26/2024 | 2017-017 |
Armenia | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Azerbaijan | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Belarus | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Eurasian Patent Office | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Kyrgyzstan | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Kazakhstan | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Russian Federation | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Tajikistan | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Turkmenistan | Issued Patent | 045278 | 11/10/2023 | 2017-017 |
Japan | Issued Patent | 7306696 | 07/03/2023 | 2017-017 |
United Kingdom | Issued Patent | 2569734 | 09/07/2022 | 2017-017 |
United States Of America | Issued Patent | 11,371,062 | 06/28/2022 | 2017-017 |
United States Of America | Published Application | 20220396812 | 12/15/2022 | 2017-017 |
Mexico | Published Application | WO 2018/064352 | 09/25/2020 | 2017-017 |
Hong Kong | Published Application | 40014082 | 08/14/2020 | 2017-017 |
Hong Kong | Published Application | 40013668A | 08/07/2020 | 2017-017 |
European Patent Office | Published Application | 3532089 A0 | 09/04/2019 | 2017-017 |
India | Published Application | 28/2019 | 07/12/2019 | 2017-017 |
Brazil | Published Application | 2529 | 06/25/2019 | 2017-017 |
Canada | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
Israel | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
Rep Of Korea | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
New Zealand | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
Saudi Arabia | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
Singapore | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
South Africa | Published Application | WO 2018/064352 | 04/05/2018 | 2017-017 |
Additional Patent Pending
The
CRISPR-Cas system is now understood to confer bacteria and archaea with
acquired immunity against phage and viruses. CRISPR-Cas systems consist of Cas
proteins, which are involved in acquisition, targeting and cleavage of foreign
DNA or RNA, and a CRISPR array, which includes direct repeats flanking short
spacer sequences that guide Cas proteins to their targets. Class 2 CRISPR-Cas are streamlined versions
in which a single Cas protein bound to RNA is responsible for binding to and cleavage
of a targeted sequence. The programmable nature of these minimal systems has
facilitated their use as a versatile technology that is revolutionizing the
field of genome manipulation. Current
CRISPR Cas technologies are based on systems from cultured bacteria, leaving untapped
the vast majority of organisms that have not been isolated. There is a need in the art for additional
Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).
UC Berkeley
researchers discovered a new type of Cas protein, CasY. CasY is short compared to previously
identified CRISPR-Cas endonucleases, and thus use of this protein as an
alternative provides the advantage that the nucleotide sequence encoding the
protein is relatively short. CasY
utilizes a guide RNA to perform double stranded cleavage of DNA. The
researchers introduced CRISPR-CasY into E. coli, finding that they could block genetic
material introduced into the cell. Further
research results indicated that CRISPR-CasY operates in a manner analogous to
CRISPR-Cas9, but utilizing an entirely distinct protein architecture containing
different catalytic domains. CasY is also
expected to function under different conditions (e.g., temperature) given the
environment of the organisms that CasY was expressed in. Similar to CRISPR Cas9, CasY enzymes are
expected to have a wide variety of applications in genome editing and nucleic
acid manipulation.
CRISPR, gene editing, genome, gene therapy, cell biology, CasY, Cas12d